Surfing-inspired saltwater mist gives relief from cystic fibrosis

Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease.

Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a new aerosol delivery system. It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.

‘We have seen evidence that routine exposure to salt water reduces the number of lung infections in CF patients and leads to fewer hospital admissions – but the challenge was to develop an optimal delivery system,’ said Dr Richard Boucher, co-founder and chairman of Parion. ‘We enlisted Cambridge Consultants to design the system…and the results have exceeded our expectations.’

CF is a chronic disease that affects the lungs and digestive system of more than 70,000 adults and children worldwide. Studies have shown that the inhalation of a hypertonic saltwater solution improves the condition of sufferers by rehydrating the layer of mucus film that lines their lungs.

Cambridge Consultants conducted human-factor studies and developed a system that could deliver an aerosol mist through the nose continuously for eight hours.

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox